---
title: "Atrium Therapeutics (RNA) news: offering and merger"
url: "https://aibio.space/companies/atrium-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RNA offering and merger news: Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share. Atrium Therapeutics, Inc."
---

RNA Atrium Therapeutics, Inc. NASDAQ · United States

# Atrium Therapeutics (RNA) news RNA offering and merger news

Financings · 2026-10-08

## [Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share](https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/)

The deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.

## Latest Atrium Therapeutics news

1. 2026-02-27 Mergers [Atrium Therapeutics completes spin-off from Avidity Biosciences, starts trading on Nasdaq as RNA](https://aibio.space/news/atrium-therapeutics-completes-spin-off-avidity-biosciences-starts/) Atrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.
2. 2026-02-26 Mergers [Atrium Therapeutics spin-off from Avidity to give holders one share per ten](https://aibio.space/news/atrium-therapeutics-spin-off-avidity-give-holders-one-share-ten/) Avidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.

## Atrium Therapeutics at a glance

- **Ticker**: RNA

- **Listing**: NASDAQ

- **Country**: United States

### Related companies

- [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) NASDAQ: CUE
- [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) NASDAQ: ELTX
- [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB
- [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) NASDAQ: MLYS
- [CNBX Pharmaceuticals](https://aibio.space/companies/cnbx-pharmaceuticals/) OTC: CNBX
- [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM
- [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB
- [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX

### Also on NASDAQ

- [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) RVMD
- [TRINITY BIOTECH](https://aibio.space/companies/trinity-biotech/) TRIB
- [Amgen](https://aibio.space/companies/amgen/) AMGN
- [EDAP TMS SA](https://aibio.space/companies/edap-tms/) FOCL
- [Jyong Biotech](https://aibio.space/companies/jyong-biotech/) MENS
- [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) SLDB

## Questions about Atrium Therapeutics

Has Atrium Therapeutics raised money recently?

Our latest story on this, dated Oct 8, 2026: "Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/).

Is Atrium Therapeutics involved in a merger or acquisition?

Our latest story on this, dated Feb 26, 2026: "Atrium Therapeutics spin-off from Avidity to give holders one share per ten". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atrium-therapeutics-spin-off-avidity-give-holders-one-share-ten/).

What is the ticker symbol of Atrium Therapeutics?

Atrium Therapeutics, Inc. trades under the ticker RNA on NASDAQ.

Where is Atrium Therapeutics listed?

Atrium Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Atrium Therapeutics?

The SEC Central Index Key (CIK) for Atrium Therapeutics, Inc. is 2093101. Its filings are on SEC EDGAR.

How many shares does Atrium Therapeutics have outstanding?

17,105,643 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Atrium Therapeutics listed under?

Our directory records Atrium Therapeutics, Inc. under United States.

What does Atrium Therapeutics do?

Our directory classifies Atrium Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Atrium Therapeutics?

The ISIN recorded for Atrium Therapeutics, Inc. is US04965N1046.

Does aibio.space cover Atrium Therapeutics?

aibio.space lists Atrium Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Atrium Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Atrium Therapeutics (RNA) stock news?

Our latest story on Atrium Therapeutics, dated Oct 8, 2026: "Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share". The deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate. [Source](https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/).

How long will Atrium Therapeutics's cash last?

From our story of Oct 8, 2026: The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate. [Source](https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/).

How much cash does Atrium Therapeutics have?

From our story of Feb 26, 2026: The unaudited pro forma balance sheet shows cash of $270,000 thousand after the transfer, against no historical cash. [Source](https://aibio.space/news/atrium-therapeutics-spin-off-avidity-give-holders-one-share-ten/).

Is Atrium Therapeutics a smaller reporting company?

SEC records list Atrium Therapeutics, Inc.'s filer category as: <br>Emerging growth company.

## Investor discussion: Atrium Therapeutics

Members talk about Atrium Therapeutics (RNA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Atrium Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2093101/000119312526417402/d25901dex991.htm)
2. 2026-02-26 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2093101/000119312526077105/d14901dex991.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RNA on TradingView](https://www.tradingview.com/symbols/NASDAQ-RNA/).

## SEC filings and registration

- **SEC name**: Atrium Therapeutics, Inc.

- **CIK**: 2093101

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RNA (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 3020 CALLAN ROAD, SAN DIEGO, CA, 92121

- **Phone**: 858-401-7900

- **Shares outstanding**: 17,105,643 as of 2026-08-03 (10-Q filed 2026-08-13)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526417402/d25901d8k.htm) filed 2026-10-08
- [10-Q](https://www.sec.gov/Archives/edgar/data/2093101/000119312526349488/rna-20260630.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/d149126d8k.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/d132402d8k.htm) filed 2026-07-14
- [10-Q](https://www.sec.gov/Archives/edgar/data/2093101/000119312526224243/rna-20260331.htm) filed 2026-05-14
- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/d82207d8k.htm) filed 2026-05-14
- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526083227/d87849d8k.htm) filed 2026-02-27
- [8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526077105/d14901d8k.htm) filed 2026-02-26

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002093101), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Atrium Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RNA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Atrium Therapeutics, Inc.

- **Ticker**: RNA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US04965N1046

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RNA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/atrium-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Atrium Therapeutics (RNA) news: offering and merger", 2026-10-31, https://aibio.space/companies/atrium-therapeutics/